{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T01:03:19Z","timestamp":1751504599766,"version":"3.37.3"},"reference-count":23,"publisher":"Japanese Society for Hygiene","issue":"0","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Environ Health Prev Med","Environ. Health Prev. Med."],"published-print":{"date-parts":[[2023]]},"DOI":"10.1265\/ehpm.23-00221","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T22:14:05Z","timestamp":1701900845000},"page":"77-77","source":"Crossref","is-referenced-by-count":3,"title":["Quality of life in patients with neurofibromatosis type 1: a nationwide database study in Japan from 2015 to 2019"],"prefix":"10.1265","volume":"28","author":[{"given":"Takashi","family":"Yamauchi","sequence":"first","affiliation":[{"name":"Department of Public Health and Environmental Medicine, The Jikei University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8392-1870","authenticated-orcid":false,"given":"Machi","family":"Suka","sequence":"additional","affiliation":[{"name":"Department of Public Health and Environmental Medicine, The Jikei University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"335","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13:834\u201343.","DOI":"10.1016\/S1474-4422(14)70063-8"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Anderson JL, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2015;132:75\u201386.","DOI":"10.1016\/B978-0-444-62702-5.00004-4"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;278:51\u20137.","DOI":"10.1001\/jama.278.1.51"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Tanito K, Ota A, Kamide R, Nakagawa H, Niimura M. Clinical features of 58 Japanese patients with mosaic neurofibromatosis 1. J Dermatol. 2014;41:724\u20138.","DOI":"10.1111\/1346-8138.12567"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ehara Y, Yamamoto O, Kosaki K, Yoshida Y. Clinical severity in Japanese patients with neurofibromatosis 1 based on DNB classification. J Dermatol. 2017;44:1262\u20137.","DOI":"10.1111\/1346-8138.13902"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Vranceanu AM, Merker VL, Park E, Plotkin SR. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neurooncol. 2013;114:257\u201362.","DOI":"10.1007\/s11060-013-1195-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Vranceanu AM, Merker VL, Park ER, Plotkin SR. Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature. J Neurooncol. 2015;122:219\u201328.","DOI":"10.1007\/s11060-015-1725-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Fournier H, Calcagni N, Morice-Picard F, Quintard B. Psychosocial implications of rare genetic skin diseases affecting appearance on daily life experiences, emotional state, self-perception and quality of life in adults: a systematic review. Orphanet J Rare Dis. 2023;18:39.","DOI":"10.1186\/s13023-023-02629-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sanagoo A, Jouybari L, Koohi F, Sayehmiri F. Evaluation of QoL in neurofibromatosis patients: a systematic review and meta-analysis study. BMC Neurol. 2019;19:123.","DOI":"10.1186\/s12883-019-1338-y"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Taylor LA, Lewis VL Jr. Neurofibromatosis Type 1: Review of Cutaneous and Subcutaneous Tumor Treatment on Quality of Life. PRS Global Open. 2019;7:e1982.","DOI":"10.1097\/GOX.0000000000001982"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yoshida Y, Ehara Y, Koga M, Imafuku S. Health-related quality of life in patients with neurofibromatosis 1 in Japan: A questionnaire survey using EQ-5D-5L. J Dermatol. 2022;49:1228\u201332.","DOI":"10.1111\/1346-8138.16510"},{"key":"12","unstructured":"12. Japan Intractable Diseases Information Center: http:\/\/www.nanbyou.or.jp\/ (2023). Accessed 20 Oct 2023. [in Japanese]."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kanatani Y, Tomita N, Sato Y, Eto A, Omoe H, Mizushima H. National registry of designated intractable diseases in Japan: present status and future prospects. Neurol Med Chir (Tokyo). 2017;57:1\u20137.","DOI":"10.2176\/nmc.st.2016-0135"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Yamauchi T, Suka M, Nishigori C, Yanagisawa H. Evaluation of neurofibromatosis type 1 progression using a nationwide registry of patients who submitted claims for medical expense subsidies in Japan between 2008 and 2012. Orphanet J Rare Dis. 2019;14:166.","DOI":"10.1186\/s13023-019-1148-8"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Okoshi H, Yamauchi T, Suka M, Saito K, Nishigori C, Yanagisawa H. Social Independence of Patients with Neurofibromatosis Type 2 in Japan: Analysis of a National Registry of Patients Receiving Medical Expense Subsidies, 2004\u20132013. Neurol Med Chir (Tokyo). 2020;60:450\u20137.","DOI":"10.2176\/nmc.oa.2020-0106"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Okoshi H, Yamauchi T, Suka M, Yanagisawa H, Fujii M, Nishigori C. Loss of social independence in patients with neurofibromatosis type 2: a follow-up study using a national registry in Japan. Environ Health Prev Med. 2023;28:46.","DOI":"10.1265\/ehpm.22-00222"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. National Institute of Health Consensus Development Conference. Neurofibromatosis Conference Statement. Arch Neurol. 1988;45:575\u20138.","DOI":"10.1001\/archneur.1988.00520290115023"},{"key":"18","unstructured":"18. EuroQol Research Foundation: EQ-5D-3L. https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-3l-about\/ (2023). Accessed 26 Jul 2023."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Wolkenstein P, Zeller J, Revuz J, Ecosse E, Lepl\u00e8ge A. Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases. Arch Dermatol. 2001;137:1421\u20135.","DOI":"10.1001\/archderm.137.11.1421"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Smith KB, Wang DL, Plotkin SR, Park ER. Appearance concerns among women with neurofibromatosis: examining sexual\/bodily and social self-consciousness. Psychooncology. 2013;22:2711\u20139.","DOI":"10.1002\/pon.3350"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Granstr\u00f6m S, Langenbruch A, Augustin M, Mautner VF. Psychological burden in adult neurofibromatosis type 1 patients: impact of disease visibility on body image. Dermatology (Basel). 2012;224:160\u20137.","DOI":"10.1159\/000337548"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Jensen SE, Patel ZS, Listernick R, Charrow J, Lai JS. Lifespan Development: Symptoms Experienced by Individuals with Neurofibromatosis Type 1 Associated Plexiform Neurofibromas from Childhood into Adulthood. J Clin Psychol Med Settings. 2019;26:259\u201370.","DOI":"10.1007\/s10880-018-9584-5"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Crawford HA, Barton B, Wilson MJ, Berman Y, McKelvey-Martin VJ, Morrison PJ, et al. The Impact of Neurofibromatosis Type 1 on the Health and Wellbeing of Australian Adults. J Genet Couns. 2015;24:931\u201344.","DOI":"10.1007\/s10897-015-9829-5"}],"container-title":["Environmental Health and Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ehpm\/28\/0\/28_23-00221\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T05:02:45Z","timestamp":1702098165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ehpm\/28\/0\/28_23-00221\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":23,"journal-issue":{"issue":"0","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1265\/ehpm.23-00221","relation":{},"ISSN":["1342-078X","1347-4715"],"issn-type":[{"type":"print","value":"1342-078X"},{"type":"electronic","value":"1347-4715"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"23-00221"}}